The effect of multifactorial, multidisciplinary educational interventions on appropriate use of teicoplanin

International Journal of Antimicrobial Agents

Volumn 27, Issue 4, 2006, Pages 344-350

  Pea, Federico ^a   Viale, Pierluigi ^a   Pavan, Federica ^a   Tavio, Marcello ^a   Poz, Donatella ^a   Beltrame, Anna ^a   Furlanut, Mario ^a  

^a Medical School   (Italy)

Author keywords

Antibiotic policy; Education; Loading dose; Teicoplanin; Therapeutic drug monitoring

Indexed keywords

ANTIBIOTIC AGENT; TEICOPLANIN;

ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL INFECTION; COMPARATIVE STUDY; CONTROLLED STUDY; CREATININE CLEARANCE; DRUG DOSE REGIMEN; DRUG INDICATION; DRUG MONITORING; DRUG USE; DRUG UTILIZATION; FEMALE; GOOD CLINICAL PRACTICE; HEALTH EDUCATION; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PATIENT EDUCATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; TREATMENT DURATION;

AGED; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; DRUG MONITORING; EDUCATION, MEDICAL, CONTINUING; FEMALE; HOSPITALS; HOSPITALS, UNIVERSITY; HUMANS; INTERVENTION STUDIES; ITALY; MALE; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; PROSPECTIVE STUDIES; TEICOPLANIN;

EID: 33646424351     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2005.11.012     Document Type: Article

References (40)

1. O'Grady N.P., Alexander M., Dellinger E.P., et al. Guidelines for the prevention of intravascular catheter-related infections. Centers for Diseases Control and Prevention. MMWR Recomm Rep 51 (2002) 1-29
2. Hanes S.D., Demirkan K., Tolley E., et al. Risk factors for late-onset nosocomial pneumonia caused by Stenotrophomonas maltophilia in critically ill trauma patients. Clin Infect Dis 35 (2002) 228-235
3. Mueller E.W., Hanes S.D., Croce M.A., Wood G.C., Boucher B.A., and Fabian T.C. Effect from multiple episodes of inadequate empiric antibiotic therapy for ventilator-associated pneumonia on morbidity and mortality among critically ill trauma patients. J Trauma 58 (2005) 94-101
4. National Nosocomial Infections Surveillance (NNIS) System report, data summary from January 1990-May 1999, issued June 1999. Am J Infect Control 1999;27:520-32.
5. American Thoracic Society; Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 171 (2005) 388-416
6. von Eiff C., Jansen B., Kohnen W., and Becker K. Infections associated with medical devices: pathogenesis, management and prophylaxis. Drugs 65 (2005) 179-214
7. Diekema D.J., Pfaller M.A., Schmitz F.J., et al. Survey of infections due to Staphylococcus species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region for the SENTRY Antimicrobial Surveillance Program, 1997-1999. Clin Infect Dis 32 (2001) S114-S132
8. Wood M.J. Chemotherapy for gram-positive nosocomial sepsis. J Chemother 11 (1999) 446-452
9. Rodriguez-Bano J. Selection of empiric therapy in patients with catheter-related infections. Clin Microbiol Infect 8 (2002) 275-281
10. Barie P.S., Hydo L.J., Shou J., Larone D.H., and Eachempati S.R. Influence of antibiotic therapy on mortality of critical surgical illness caused or complicated by infection. Surg Infect (Larchmt) 6 (2005) 41-54
11. Pea F., Brollo L., Viale P., Pavan F., and Furlanut M. Teicoplanin therapeutic drug monitoring in critically ill patients: a retrospective study emphasizing the importance of a loading dose. J Antimicrob Chemother 51 (2003) 971-975
12. Belzberg H., Zhu J., Cornwell III E.E., et al. Imipenem levels are not predictable in the critically ill patient. J Trauma 56 (2004) 111-117
13. Pea F., Viale P., and Furlanut M. Antimicrobial therapy in critically ill patients: a review of pathophysiological conditions responsible for altered disposition and pharmacokinetic variability. Clin Pharmacokinet 44 (2005) 1009-1034
14. Schentag J.J. Antimicrobial management strategies for Gram-positive bacterial resistance in the intensive care unit. Crit Care Med 29 (2001) N100-N107
15. Awni W.M., St Peter W.L., Guay D.R., Kenny M.T., and Matzke G.R. Teicoplanin measurement in patients with renal failure: comparison of fluorescence polarization immunoassay, microbiological assay, and high-performance liquid chromatographic assay. Ther Drug Monit 13 (1991) 511-517
16. Cox H., Whitby M., Nimmo G., and Williams G. Evaluation of a novel fluorescence polarization immunoassay for teicoplanin. Antimicrob Agents Chemother 37 (1993) 1924-1926
17. MacGowan A.P., McMullin C.M., White L.O., Reeves D.S., Davis E., and Speller D.C. Serum monitoring of teicoplanin. J Antimicrob Chemother 30 (1992) 399-402
18. Begg E.J., Barclay M.L., and Kirkpatrick C.M. The therapeutic monitoring of antimicrobial agents. Br J Clin Pharmacol 52 (2001) 35S-43S
19. Wilson A.P. Clinical pharmacokinetics of teicoplanin. Clin Pharmacokinet 39 (2000) 167-183
20. MacGowan A.P. Pharmacodynamics, pharmacokinetics, and therapeutic drug monitoring of glycopeptides. Ther Drug Monit 20 (1998) 473-477
21. Wilson A.P.R., Gruneberg R.N., and Neu H. A critical review of the dosage of teicoplanin in Europe and the USA. Int J Antimicrob Agents 4 (1994) S1-S30
22. Pea F., Viale P., Candoni A., et al. Teicoplanin in patients with acute leukaemia and febrile neutropenia: a special population benefiting from higher dosages. Clin Pharmacokinet 43 (2004) 405-415
23. Schaison G., Graninger W., and Bouza E. Teicoplanin in the treatment of serious infection. J Chemother 12 (2000) 26-33
24. Wilson A.P., Gruneberg R.N., and Neu H. Dosage recommendations for teicoplanin. J Antimicrob Chemother 32 (1993) 792-796
25. MacGowan A.P., and Bowker K.E. Pharmacodynamics of antimicrobial agents and rationale for their dosing. J Chemother 9 (1997) 64-73
26. Cockcroft D.W., and Gault M.H. Prediction of creatinine clearance from serum creatinine. Nephron 16 (1976) 31-41
27. Gyssens I.C., Blok W.L., van den Broek P.J., Hekster Y.A., and van der Meer J.W. Implementation of an educational program and an antibiotic order form to optimize quality of antimicrobial drug use in a department of internal medicine. Eur J Clin Microbiol Infect Dis 16 (1997) 904-912
28. Barenfanger J., Short M.A., and Groesch A.A. Improved antimicrobial interventions have benefits. J Clin Microbiol 39 (2001) 2823-2828
29. Berild D., Ringertz S.H., Lelek M., and Fosse B. Antibiotic guidelines lead to reductions in the use and cost of antibiotics in a university hospital. Scand J Infect Dis 33 (2001) 63-67
30. Feucht C.L., and Rice L.B. An interventional program to improve antibiotic use. Ann Pharmacother 37 (2003) 646-651
31. Bantar C., Sartori B., Vesco E., et al. A hospitalwide intervention program to optimize the quality of antibiotic use: impact on prescribing practice, antibiotic consumption, cost savings, and bacterial resistance. Clin Infect Dis 37 (2003) 180-186
32. Welschen I., Kuyvenhoven M.M., Hoes A.W., and Verheij T.J. Effectiveness of a multiple intervention to reduce antibiotic prescribing for respiratory tract symptoms in primary care: randomised controlled trial. BMJ 329 (2004) 431
33. Lutters M., Harbarth S., Janssens J.P., et al. Effect of a comprehensive, multidisciplinary, educational program on the use of antibiotics in a geriatric university hospital. J Am Geriatr Soc 52 (2004) 112-116
34. Petrak R.M., Sexton D.J., Butera M.L., et al. The value of an infectious diseases specialist. Clin Infect Dis 36 (2003) 1013-1017
35. Kollef M.H. Optimizing antibiotic therapy in the intensive care unit setting. Crit Care 5 (2001) 189-195
36. Niederman M.S. Appropriate use of antimicrobial agents: challenges and strategies for improvement. Crit Care Med 31 (2003) 608-616
37. Leibovici L., Shraga I., Drucker M., Konigsberger H., Samra Z., and Pitlik S.D. The benefit of appropriate empirical antibiotic treatment in patients with bloodstream infection. J Intern Med 244 (1998) 379-386
38. Harbarth S., Garbino J., Pugin J., Romand J.A., Lew D., and Pittet D. Inappropriate initial antimicrobial therapy and its effect on survival in a clinical trial of immunomodulating therapy for severe sepsis. Am J Med 115 (2003) 529-535
39. Iregui M., Ward S., Sherman G., Fraser V.J., and Kollef M.H. Clinical importance of delays in the initiation of appropriate antibiotic treatment for ventilator-associated pneumonia. Chest 122 (2002) 262-268
40. Kollef M.H., and Micek S.T. Strategies to prevent antimicrobial resistance in the intensive care unit. Crit Care Med 33 (2005) 1845-1853